文献速递淋巴瘤

靶向ZDHHC21/FASN轴治疗弥漫性大B细胞淋巴瘤

Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma.
PubMed 文献 · Leukemia · 2024-01-09

本研究揭示棕榈酰转移酶ZDHHC21在弥漫性大B细胞淋巴瘤(DLBCL)中作为抑癌因子,其表达下调并与患者临床预后相关。ZDHHC21与脂肪酸合成酶(FASN)相互作用并介导其Cys1317位点棕榈酰化,降低FASN蛋白稳定性及脂肪酸合成,从而抑制DLBCL细胞增殖;FDA批准的小分子化合物毛花洋地黄苷C可稳定ZDHHC21、降低FASN表达并抑制DLBCL生长。

要点

  • ZDHHC21在DLBCL中表达下调,其水平与患者临床预后相关。
  • ZDHHC21介导FASN Cys1317棕榈酰化,降低FASN稳定性并抑制脂肪酸合成。
  • 毛花洋地黄苷C与ZDHHC21结合,稳定其蛋白并降低FASN表达,抑制DLBCL生长。

核心结论

  • ZDHHC21通过介导FASN棕榈酰化强烈抑制DLBCL细胞增殖,靶向ZDHHC21/FASN轴是潜在的治疗策略。

研究设计与样本

  • 研究采用体外和体内实验,探讨ZDHHC21在DLBCL中的作用及其与FASN的相互作用机制,并测试FDA批准的小分子化合物毛花洋地黄苷C的效果。

主要发现

  • ZDHHC21在DLBCL中表达下调,其表达水平与DLBCL患者的临床预后相关。
  • 体外和体内实验表明ZDHHC21抑制DLBCL细胞增殖。
  • ZDHHC21与FASN相互作用并介导其Cys1317位点棕榈酰化,导致FASN蛋白稳定性下降和脂肪酸合成减少,从而抑制DLBCL细胞生长。
  • FDA批准的小分子化合物毛花洋地黄苷C与ZDHHC21相互作用,增加ZDHHC21蛋白稳定性并降低FASN表达,在体外和体内抑制DLBCL生长。

临床怎么用

  • 作者认为靶向ZDHHC21/FASN轴是抗DLBCL的潜在治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

S-palmitoylation is essential for cancer development via regulating protein stability, function and subcellular location, yet the roles S-palmitoylation plays in diffuse large B-cell lymphoma (DLBCL) progression remain enigmatic. In this study, we uncovered a novel function of the palmitoyltransferase ZDHHC21 as a tumor suppressor in DLBCL and identified ZDHHC21 as a key regulator of fatty acid synthetase (FASN) S-palmitoylation for the first time. Specifically, ZDHHC21 was downregulated in DLBCL, and its expression level was associated with the clinical prognosis of patients with DLBCL. In vitro and in vivo experiments suggested that ZDHHC21 suppressed DLBCL cell proliferation. Mechanistically, ZDHHC21 interacted with FASN and mediated its palmitoylation at Cys1317, resulting in a decrease in FASN protein stability and fatty acid synthesis, consequently leading to the inhibition of DLBCL cell growth. Of note, an FDA-approved small-molecule compound lanatoside C interacted with ZDHHC21, increased ZDHHC21 protein stability and decreased FASN expression, which contributed to the suppression of DLBCL growth in vitro and in vivo. Our results demonstrate that ZDHHC21 strongly represses DLBCL cell proliferation by mediating FASN palmitoylation, and suggest that targeting ZDHHC21/FASN axis is a potential therapeutic strategy against DLBCL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Liu B, Zhao X, Zhang S, et al. Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma. Leukemia. 2024. PMID: 38195819. doi:10.1038/s41375-023-02130-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。